• Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Cys (c.37G>T); ClinVar=VCV000045123; Zygosity=Unspecified (PubMed=20088962).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Pro153Ser (c.457C>T); ClinVar=VCV000422563; Zygosity=Unspecified (PubMed=20088962).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Thr155Pro (c.463A>C); Zygosity=Unspecified (PubMed=20088962).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Unspecified (PubMed=20088962).
  

PubMed=20088962; DOI=10.1111/j.1349-7006.2009.01462.x
Ojima H., Yoshikawa D., Ino Y., Shimizu H., Miyamoto M., Kokubu A., Hiraoka N., Morofuji N., Kondo T., Onaya H., Okusaka T., Shimada K., Sakamoto Y., Esaki M., Nara S., Kosuge T., Hirohashi S., Kanai Y., Shibata T.
Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment.
Cancer Sci. 101:882-888(2010)

CLPUB00275
Zach S., Birgin E., Ruckert F.
Primary cholangiocellular carcinoma cell lines.
J. Stem Cell Res. Transplant. 2:1013-1013(2015)

PubMed=26141945; DOI=10.1158/1535-7163.MCT-15-0069
Shirota T., Ojima H., Hiraoka N., Shimada K., Rokutan H., Arai Y., Kanai Y., Miyagawa S., Shibata T.
Heat shock protein 90 is a potential therapeutic target in cholangiocarcinoma.
Mol. Cancer Ther. 14:1985-1993(2015)

PubMed=27833395; DOI=10.3748/wjg.v22.i40.9035
Ojima H., Yamagishi S., Shimada K., Shibata T.
Establishment of various biliary tract carcinoma cell lines and xenograft models for appropriate preclinical studies.
World J. Gastroenterol. 22:9035-9038(2016)

PubMed=35640676; DOI=10.1016/j.ajpath.2022.05.007
Isidan A., Yenigun A., Soma D., Aksu E., Lopez K., Park Y., Cross-Najafi A., Li P., Kundu D., House M.G., Chakraborty S., Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.
Development and characterization of human primary cholangiocarcinoma cell lines.
Am. J. Pathol. 192:1200-1217(2022)